1 Arzneimittelinformation Schweiz,
www.swissmedicinfo.ch.
2 Kalil AC. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics [published online ahead of print, 2020 Mar 24]. JAMA. 2020;10.1001/jama.2020.4742.
doi:10.1001/jama.2020.4742.
3 Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020.
doi:10.1093/cid/ciaa237.
4 Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. Published 2020 Mar 18.
doi:10.1038/s41421-020-0156-0.
5 Gautret P, Lagiera JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020.
doi:10.1016/j.ijantimicag.2020.105949.
6 Lim HS, Im JS, Cho JY, et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009; 53(4):1468–75.
7 Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit. 2003;25(6):671–81.
8 Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. Am J Trop Med Hyg. 2020;102(6):1156–7.
doi:10.4269/ajtmh.20-0271.
9 Garcia-Cremades M, Solans BP, Hughes E, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther. 2020;10.1002/cpt.1856.
doi:10.1002/cpt.1856. [published online ahead of print, 2020 Apr 14].
10 Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1460–9.
doi:10.1002/art.10307.
11 Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19 [published online ahead of print March 25, 2020]. Mayo Clin Proc. 2020;95(6):1213–21.
https://doi.org/10.1016/j.mayocp.2020.03.024.
12 European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 21 April 2020,
https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance.
14 Böck H. About that Hydroxychloroquine for COVID-19 trial. In: Better Science. 23. März 2020,
https://betterscience.org/archives/11-About-that-Hydroxychloroquine-for-COVID-19-trial.html.
15 Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base [published online ahead of print, 2020 Apr 15]. Lancet Respir Med. 2020;S2213-2600(20)30172-7.
doi:10.1016/S2213-2600(20)30172-7.
16 Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020;369:m1432. Published 2020 Apr 8.
doi:10.1136/bmj.m1432.
17 Mégarbane B. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. Clin Toxicol (Phila). 2020;1–2.
doi:10.1080/15563650.2020.1748194. [published online ahead of print, 2020 Apr 2].
18 International Society of Antimicrobial Chemotherapy (ISAC) / Elsevier. Joint ISAC and Elsevier statement on Gautret et al. paper [PMID 32205204].
https://www.isac.world/news-and-publications/official-isac-statement.
19 Owens B. Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology. The Lancet Rheumatology.
https://doi.org/10.1016/S2665-9913(20)30089-8
20 The New York Times. Vaccine Chief Says He Was Removed After Questioning Drug Trump Promoted.
https://www.nytimes.com/2020/04/22/us/coronavirus-live-coverage.html?smid=tw-share.
21 Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. 2020.
https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf.
22 Molina JM, Delaugerre C, Goff JL, et al. No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection. Med Mal Infect. 2020Jun;50(4):384.
doi:10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.. 2020.
23 Chen J, Lui D, Lui L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215–9.
24 Chen Z, Hu J, Zhang Z, et al. Efficacy of hydrochloroquine in patients with COVID-19: Results of a randomized trial. Published online,
https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2.
25 Sarma P, Kaur H, Kumar H, et al. Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis. J Med Virol. 2020;10.1002/jmv.25898.
doi:10.1002/jmv.25898. [published online ahead of print, 2020 Apr 16].
26 Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844. Published 2020 May 14.
doi:10.1136/bmj.m1844.
27 Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;NEJMoa2012410.
doi:10.1056/NEJMoa2012410. [published online ahead of print, 2020 May 7].
28 Konig MF, Kim AH, Scheetz MH, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020;annrheumdis-2020-217690.
doi:10.1136/annrheumdis-2020-217690. [published online ahead of print, 2020 May 7].
29 Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [published online ahead of print, 2020 May 22] [published correction appears in Lancet. 2020 May 30]. Lancet. 2020;S0140-6736(20)31180-6.
doi:10.1016/S0140-6736(20)31180-6.
30 Open letter to MR Mehra, SS Desai, F Ruschitzka, and AN Patel, authors of «Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis». Lancet. 2020 May 22: S0140-6736(20)31180-6.
doi:10.1016/S0140-6736(20)31180-6. PMID: 3245107 and to Richard Horton (editor of The Lancet).
https://zenodo.org/record/3862789#.XtkSsyWxWEc.
31 Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020.
https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf.
33 Nassim N. Taleb. The Bed of Procrustes: Philosophical and Practical Aphorisms (2010).
34 US Food & Drug Administration (FDA). Fact sheet for health care providers emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. US Food & Drug Administration (FDA). Silver Spring, MD. 2020.